Technology offer : Rapid diagnostic test for American Tegumentary Leishmaniasis.

Technology's description

Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania and transmitted by the bite of certain species of the sand fly. Leishmaniasis is considered as a global burden in many regions such as South America,the Mediterranean basin, and the Middle East and Central Asia. The WHO estimated 1.3 million new cases and 20 000 to 30 000 deaths occur annually. The present invention relates to peptides and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, especially infection with a South American strain causing the American Tegumentary Leishmaniasis. The research team selected two peptides which are specificaly reconized by anti-leishmania sera. First tests on ELISA using those 2 petptides show a sensitivity of 84,5% and a specificity of 94%. The  team is actually looking for partners with the ability to developped a rapid diagnostic test using this two antigenic-peptides.



Advantages

  • Field adapted diagnostic
  • Few final products can be developed from this technology
  • Major public health concern in many regions
  • Massive network and sera available to test the diagnostic
  • Distributor available in Peru
Ref : OT-00027

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Diptstick test for American Tegumentary Leishmaniasis.

Intellectual property

  • Patent field application

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27